The FTSE 100 index dropped by 0.3% on Tuesday, primarily influenced by GSK's decision to acquire U.S.-based drug developer Nuvalent for $10.6 billion. The acquisition is part of GSK's strategy to enhance its lung cancer treatment portfolio.

GSK plc (NYSE:GSK) agreed to acquire IDRx, Inc., a biopharmaceutical company focused on precision therapeutics for gastrointestinal stromal tumors (GIST), for $1 billion. Under the agreement, GSK could pay an additional $150 million based on regulatory ...